Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Doroshow, James H."'
Autor:
Mittra A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Division of Medical Oncology, The Ohio State University, Columbus, OH, 43210, USA., Coyne GHOS; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Zlott J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Meehan R; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Rubinstein L; Biometric Research Program, National Cancer Institute, Bethesda, MD, 20892, USA., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Wilsker D; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Ji J; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Miller B; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Navas T; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA., Ferry-Galow KV; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Jiwani S; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Parchment RE; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA. chenali@mail.nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Mar; Vol. 93 (3), pp. 177-189. Date of Electronic Publication: 2023 Nov 27.
Autor:
Do KT; Dana-Farber Cancer Institute, Boston, MA, USA. Khanh_Do@dfci.harvard.edu.; Center for Cancer Therapeutic Innovation, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue -DA2010, Boston, MA, 02215, USA. Khanh_Do@dfci.harvard.edu., O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Hays JL; The Ohio State University Wexner Medical Center, Columbus, OH, USA., Supko JG; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Liu SV; Georgetown University Medical Center, Washington, DC, USA., Beebe K; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Neckers L; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Trepel JB; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Lee MJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Smyth T; Astex Pharmaceuticals, Cambridge, UK., Gannon C; Dana-Farber Cancer Institute, Boston, MA, USA., Hedglin J; Dana-Farber Cancer Institute, Boston, MA, USA., Muzikansky A; Massachusetts General Hospital Biostatistics Center, Boston, MA, USA., Campos S; Dana-Farber Cancer Institute, Boston, MA, USA., Lyons J; Astex Pharmaceuticals, Cambridge, UK., Ivy P; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Shapiro GI; Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Dec; Vol. 86 (6), pp. 815-827. Date of Electronic Publication: 2020 Oct 23.
Autor:
Coyne GO'; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Wang L; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zlott J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Juwara L; Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Beumer JH; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA., Cristea MC; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA., Newman EM; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA., Koehler S; City of Hope Medical Group, South Pasadena, CA, USA., Nieva JJ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Garcia AA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.; Louisiana State University, New Orleans, LA, 70112, USA., Gandara DR; University of California Davis Cancer Center, Sacramento, CA, USA., Miller B; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Khin S; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Miller SB; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Steinberg SM; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Rubinstein L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Piekarz RL; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA. doroshoj@mail.nih.gov.; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. doroshoj@mail.nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 979-993. Date of Electronic Publication: 2020 Apr 20.
Autor:
Min DJ; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA., Zhao Y; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA., Monks A; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Palmisano A; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA., Hose C; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Teicher BA; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Simon RM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA. richard.simon@nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Oct; Vol. 84 (4), pp. 771-780. Date of Electronic Publication: 2019 Jul 31.
Autor:
Evans DM; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Fang J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA., Silvers T; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Delosh R; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Laudeman J; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Ogle C; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Reinhart R; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Selby M; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Bowles L; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Connelly J; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Harris E; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Krushkal J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA., Doroshow JH; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA., Teicher BA; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA. Beverly.Teicher@nih.gov.; Molecular Pharmacology Branch, National Cancer Institute, RM 4-W602, MSC 9735, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. Beverly.Teicher@nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Aug; Vol. 84 (2), pp. 359-371. Date of Electronic Publication: 2019 May 17.
Autor:
Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Chen A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Gutierrez M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Pfister TD; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wang L; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Redon C; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bonner WM; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yutzy W; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zhang Y; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Ji J; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Allen D; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Eiseman JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Holleran JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Rubinstein L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Collins J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Tomaszewski J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Parchment R; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Pommier Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA. doroshoj@mail.nih.gov.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. doroshoj@mail.nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Jul; Vol. 78 (1), pp. 73-81. Date of Electronic Publication: 2016 May 11.
Autor:
Holleran JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. beumerj@gmail.com., McCormick DL; IIT Research Institute, 10 West 35th Street, Chicago, IL, 60616, USA., Johnson WD; IIT Research Institute, 10 West 35th Street, Chicago, IL, 60616, USA., Newman EM; Department of Cancer Biology, City of Hope Beckman Research Institute, 1500 East Duarte Road, Duarte, CA, 91010, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Covey JM; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Davis M; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Eiseman JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA. eisemanj@upmc.edu.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. eisemanj@upmc.edu.; University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27B, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. eisemanj@upmc.edu.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Oct; Vol. 76 (4), pp. 803-11. Date of Electronic Publication: 2015 Sep 01.
Autor:
Newman EM; Department of Molecular Pharmacology, City of Hope Beckman Research Institute, 1500 East Duarte Road, Duarte, CA, 91010-3000, USA, enewman@coh.org., Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Mar; Vol. 75 (3), pp. 537-46. Date of Electronic Publication: 2015 Jan 08.
Autor:
Jeong W; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Feb; Vol. 73 (2), pp. 343-8. Date of Electronic Publication: 2013 Nov 30.
Autor:
Kummar S; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2013 Oct; Vol. 72 (4), pp. 917-23. Date of Electronic Publication: 2013 Aug 03.